Arrowhead Pharmaceuticals Inc. (ARWR) cratered nearly 60% in the after-hours session on Tuesday, following announcement that the development of clinical stage drug candidates ARC-520 and ARC-521, being developed for treatment of hepatitis B, and ARC-AAT, being developed to treat liver disease associated with Alpha-1 Antitrypsin Deficiency, will be discontinued.
from RTT - Biotech http://ift.tt/2gUbLcg
via IFTTT
No comments:
Post a Comment